There are 2789 resources available
1014P - Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in previously untreated patients with metastatic uveal melanoma
Presenter: April Salama
Session: ePoster Display
1015P - A phase I dose-escalation study of HBM4003: An anti-CTLA-4 heavy-chain-only mAb
Presenter: Paul de Souza
Session: ePoster Display
1016P - ImmTAC redirect exhausted tumor-infiltrating T-cells: An effect enhanced by pembrolizumab against PD-L1+ tumors
Presenter: Kristina Petrovic
Session: ePoster Display
1017P - Preclinical evaluation of KD033, a human anti-PD-L1/IL-15 bispecific protein, in human PD-1/PD-L1 transgenic C57/Bl6 mice with PD-L1 positive and negative tumors
Presenter: Stella Martomo
Session: ePoster Display
1018P - Characterization of liver function tests following tebentafusp in phase III randomized trial comparing tebentafusp with investigator’s choice in first line metastatic uveal melanoma (mUM)
Presenter: Bartosz Chmielowski
Session: ePoster Display
1019P - Selection of the optimal dose for ALX148, a CD47 blocker, using pharmacokinetic/pharmacodynamic modeling
Presenter: Oleg Demin Jr
Session: ePoster Display
1020P - MPT-0118 a clinical drug candidate to assess Treg reprogramming via MALT1 blockade
Presenter: Peter Keller
Session: ePoster Display
1021P - Long non-coding RNAs influence cancer immunotherapy efficacy through regulating T-cell infiltration and activity or tumor antigenicity
Presenter: Anlin Li
Session: ePoster Display
1022P - Frequency of PD1-negative and PD-1-positive ILCs in breast cancer patients depending on PD-L1 status
Presenter: Vladimir Alifanov
Session: ePoster Display
1023P - A novel microbiome-derived peptide, SG-3-00802 reverses resistance to anti-programmed death protein-1 (PD-1) therapy
Presenter: Helena Kiefel
Session: ePoster Display